ACCEPTABILITY OF AND PREFERENCES FOR LONG-ACTING INJECTABLE HORMONAL CONTRACEPTION: RESULTS FROM A NATIONAL ONLINE SURVEY WITH US WOMEN

IF 2.8 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Contraception Pub Date : 2024-10-07 DOI:10.1016/j.contraception.2024.110635
A Gottert, T Abuya, E Proos, I Johnson, NH Dormer, U Foley, G Saul, LB Haddad, DR Friend
{"title":"ACCEPTABILITY OF AND PREFERENCES FOR LONG-ACTING INJECTABLE HORMONAL CONTRACEPTION: RESULTS FROM A NATIONAL ONLINE SURVEY WITH US WOMEN","authors":"A Gottert,&nbsp;T Abuya,&nbsp;E Proos,&nbsp;I Johnson,&nbsp;NH Dormer,&nbsp;U Foley,&nbsp;G Saul,&nbsp;LB Haddad,&nbsp;DR Friend","doi":"10.1016/j.contraception.2024.110635","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>We conducted end-user research to optimize design of a sustained-release microsphere-based etonogestrel long-acting injectable (LAI) in development targeting 6- or 12-month windows of protection, steady hormone dose, and rapid return-to-fertility.</div></div><div><h3>Methods</h3><div>We implemented a national online survey including a discrete choice experiment (DCE) in June-July 2023, with cis-gender women ages 18-44 years. DCE attributes included duration of effectiveness (6/12/24-months), effect on menses, side-effects, and post-use return-to-fertility timing. Data analysis employed mixed-multinomial logit models.</div></div><div><h3>Results</h3><div>1,029 participants completed the survey (mean age 28.6 years, from 49 US states; 30.9% Black/African American; 11.6% Hispanic/Latina; 71.6% nulliparous; 49.0% not wanting a(nother) child). 35.7% currently use birth-control pills (37.4%); 35.7% male condoms; 19.8% withdrawal. In the DCE, participants strongly negatively preferred (in order-of-magnitude): may cause heavier/unpredictable periods, mild headaches/nausea, slight weight-gain, and delayed return-to-fertility (6-12-months vs. 3-months). Participants positively preferred: may cause no period, and shorter/lighter periods. Women significantly preferred 12-month to 6-month duration (p&lt;0.03). Most participants (92.4%) were interested in using the LAI if it had no/minimal side-effects/heavier bleeding and quick return-to-fertility. Two-thirds preferred a 12/24-month duration; one-third a 6-month. Preference for 6-month duration was associated with wanting a child within five years, and higher discomfort with hormones (both p&lt;0.001).</div></div><div><h3>Conclusions</h3><div>While most women report interest in an LAI, interest substantially decreases if it may cause heavier/unpredictable periods, other side-effects, or delayed return-to-fertility. Longer duration (12+ months) is preferred; a 6-month option appears important for women wanting to get pregnant relatively soon, and those concerned about hormones.</div></div>","PeriodicalId":10762,"journal":{"name":"Contraception","volume":"139 ","pages":"Article 110635"},"PeriodicalIF":2.8000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contraception","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0010782424003305","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

We conducted end-user research to optimize design of a sustained-release microsphere-based etonogestrel long-acting injectable (LAI) in development targeting 6- or 12-month windows of protection, steady hormone dose, and rapid return-to-fertility.

Methods

We implemented a national online survey including a discrete choice experiment (DCE) in June-July 2023, with cis-gender women ages 18-44 years. DCE attributes included duration of effectiveness (6/12/24-months), effect on menses, side-effects, and post-use return-to-fertility timing. Data analysis employed mixed-multinomial logit models.

Results

1,029 participants completed the survey (mean age 28.6 years, from 49 US states; 30.9% Black/African American; 11.6% Hispanic/Latina; 71.6% nulliparous; 49.0% not wanting a(nother) child). 35.7% currently use birth-control pills (37.4%); 35.7% male condoms; 19.8% withdrawal. In the DCE, participants strongly negatively preferred (in order-of-magnitude): may cause heavier/unpredictable periods, mild headaches/nausea, slight weight-gain, and delayed return-to-fertility (6-12-months vs. 3-months). Participants positively preferred: may cause no period, and shorter/lighter periods. Women significantly preferred 12-month to 6-month duration (p<0.03). Most participants (92.4%) were interested in using the LAI if it had no/minimal side-effects/heavier bleeding and quick return-to-fertility. Two-thirds preferred a 12/24-month duration; one-third a 6-month. Preference for 6-month duration was associated with wanting a child within five years, and higher discomfort with hormones (both p<0.001).

Conclusions

While most women report interest in an LAI, interest substantially decreases if it may cause heavier/unpredictable periods, other side-effects, or delayed return-to-fertility. Longer duration (12+ months) is preferred; a 6-month option appears important for women wanting to get pregnant relatively soon, and those concerned about hormones.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
长效注射荷尔蒙避孕药的可接受性和偏好:对美国妇女进行的全国性在线调查的结果
目标我们开展了最终用户研究,以优化正在开发的基于微球的缓释依托诺孕酮长效注射剂(LAI)的设计,该注射剂具有 6 个月或 12 个月的保护期、稳定的激素剂量和快速恢复受孕能力。方法我们于 2023 年 6 月至 7 月开展了一项全国在线调查,其中包括离散选择实验(DCE),调查对象为 18-44 岁的顺性别女性。离散选择实验的属性包括有效期(6/12/24 个月)、对月经的影响、副作用和使用后恢复生育的时间。数据分析采用了混合多项式对数模型。结果 1,029 名参与者完成了调查(平均年龄 28.6 岁,来自美国 49 个州;30.9% 为黑人/非裔美国人;11.6% 为西班牙裔/拉丁裔美国人;71.6% 为未婚先孕;49.0% 不想要孩子)。35.7%的人目前使用避孕药(37.4%);35.7%的人使用男用避孕套;19.8%的人不使用避孕药。在 DCE 中,参与者强烈反对(按程度排序):可能导致月经量增多/无法预测、轻微头痛/恶心、体重轻微增加、推迟恢复生育(6-12 个月与 3 个月)。参与者更倾向于选择:可能导致无月经,月经期更短/月经量更少。与 6 个月的疗程相比,女性更倾向于 12 个月的疗程(p<0.03)。如果LAI无副作用/副作用小/出血量较多,且能快速恢复生育能力,大多数参与者(92.4%)都有兴趣使用LAI。三分之二的人选择 12/24 个月的疗程,三分之一的人选择 6 个月。结论虽然大多数女性表示对 LAI 感兴趣,但如果它可能导致月经量增多/无法预测、其他副作用或推迟恢复生育,那么兴趣就会大大降低。较长的疗程(12 个月以上)是首选;6 个月的疗程对于希望尽快怀孕的妇女和担心荷尔蒙的妇女来说似乎很重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Contraception
Contraception 医学-妇产科学
CiteScore
4.70
自引率
17.20%
发文量
211
审稿时长
69 days
期刊介绍: Contraception has an open access mirror journal Contraception: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. The journal Contraception wishes to advance reproductive health through the rapid publication of the best and most interesting new scholarship regarding contraception and related fields such as abortion. The journal welcomes manuscripts from investigators working in the laboratory, clinical and social sciences, as well as public health and health professions education.
期刊最新文献
Editorial Board Copyright info/Contents Editorial Board Copyright info/Contents Society of Family Planning Committee Statement: Contraception and body weight
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1